Frequently asked questions about VERQUVO\u00ae (vericiguat)<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\nFor answers to questions you may have, select any of the topics below. To see a complete list of FAQs, scroll down.<\/p>\n\n\n\n
<\/div>\n\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the indication and usage for VERQUVO?<\/h4><\/summary>\nVERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n\n
<\/div>\n\n\n\n See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Selected Safety Information for VERQUVO?<\/h4><\/summary>\n\n\n\nWARNING: EMBRYO-FETAL TOXICITY <\/strong><\/h4>\nFemales of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n<\/div><\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\n- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- VERQUVO is contraindicated in pregnancy.<\/li>
- Embryo-Fetal Toxicity:<\/strong> Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.<\/li>
- There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231<\/span> or at https:\/\/pregnancyreporting.verquvo-us.com<\/mark><\/span><\/a>.<\/li>
- In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency \u22655%, were hypotension (16% vs 15%) and anemia (10% vs 7%).<\/li>
- Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.<\/li>
- There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.<\/li><\/ul><\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the recommended dosing for VERQUVO?<\/h4><\/summary>\nThe recommended starting dose of VERQUVO is 5 mg orally once daily with food. For patients at risk of symptomatic hypotension, the recommended starting dose is 2.5 mg orally once daily with food. Double the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.<\/p>\n\n\n\n
<\/div>\n\n\n\nSee dosing for VERQUVO.<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What are the contraindications for VERQUVO?<\/h4><\/summary>\n- Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- Pregnancy<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What are the drug interactions listed for VERQUVO?<\/h4><\/summary>\nVERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators [see Contraindications above]. <\/p>\n\n\n\n
<\/div>\n\n\n\nConcomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension. <\/p>\n\n\n\n
<\/div>\n\n\n\n
For answers to questions you may have, select any of the topics below. To see a complete list of FAQs, scroll down.<\/p>\n\n\n\n
What is the indication and usage for VERQUVO?<\/h4><\/summary>\nVERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n\n
<\/div>\n\n\n\n See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Selected Safety Information for VERQUVO?<\/h4><\/summary>\n\n\n\nWARNING: EMBRYO-FETAL TOXICITY <\/strong><\/h4>\nFemales of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n<\/div><\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\n- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- VERQUVO is contraindicated in pregnancy.<\/li>
- Embryo-Fetal Toxicity:<\/strong> Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.<\/li>
- There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231<\/span> or at https:\/\/pregnancyreporting.verquvo-us.com<\/mark><\/span><\/a>.<\/li>
- In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency \u22655%, were hypotension (16% vs 15%) and anemia (10% vs 7%).<\/li>
- Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.<\/li>
- There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.<\/li><\/ul><\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the recommended dosing for VERQUVO?<\/h4><\/summary>\nThe recommended starting dose of VERQUVO is 5 mg orally once daily with food. For patients at risk of symptomatic hypotension, the recommended starting dose is 2.5 mg orally once daily with food. Double the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.<\/p>\n\n\n\n
<\/div>\n\n\n\nSee dosing for VERQUVO.<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What are the contraindications for VERQUVO?<\/h4><\/summary>\n- Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- Pregnancy<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What are the drug interactions listed for VERQUVO?<\/h4><\/summary>\nVERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators [see Contraindications above]. <\/p>\n\n\n\n
<\/div>\n\n\n\nConcomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension. <\/p>\n\n\n\n
<\/div>\n\n\n\n
VERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n\n
See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\n Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n<\/div><\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n The recommended starting dose of VERQUVO is 5 mg orally once daily with food. For patients at risk of symptomatic hypotension, the recommended starting dose is 2.5 mg orally once daily with food. Double the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.<\/p>\n\n\n\n See dosing for VERQUVO.<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\n See Prescribing Information for VERQUVO<\/a><\/p>\n<\/div><\/details><\/div>\n\n\n\n VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators [see Contraindications above]. <\/p>\n\n\n\n Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension. <\/p>\n\n\n\nWhat is the Selected Safety Information for VERQUVO?<\/h4><\/summary>
WARNING: EMBRYO-FETAL TOXICITY <\/strong><\/h4>
What is the recommended dosing for VERQUVO?<\/h4><\/summary>
What are the contraindications for VERQUVO?<\/h4><\/summary>
What are the drug interactions listed for VERQUVO?<\/h4><\/summary>
![\"\"\/](\"https:\/\/www.merckconnect.com\/verquvo\/wp-content\/uploads\/sites\/67\/2025\/12\/desk-new.png\")
<\/picture>